Suppr超能文献

年龄会影响乳腺癌的预后吗?

Does age affect outcome with breast cancer?

机构信息

BC Cancer Vancouver Centre, Vancouver, BC, Canada; University of British Columbia, Canada.

Breast Cancer Outcomes Unit, BC Cancer, Vancouver, BC, Canada.

出版信息

Breast. 2023 Aug;70:25-31. doi: 10.1016/j.breast.2023.06.001. Epub 2023 Jun 2.

Abstract

Prior data about the influence of age at diagnosis of breast cancer on patient outcomes and survival has been conflicting. Using the Breast Cancer Outcomes Unit database at BC Cancer, this retrospective population-based study identified a cohort of 24,469 patients diagnosed with invasive breast cancer between 2005 and 2014. Median follow-up was 11.5 years. We analyzed clinical and pathological features at diagnosis and treatment specific variables compared across the following age cohorts: <35, 35-39, 40-49, 50-59, 60-69, 70-79, and 80 years of age and older. We assessed the impact of age on breast cancer specific survival (BCSS) and overall survival (OS) by age and subtype. There were distinct clinical-pathological and treatment pattern differences at both extremes of age at diagnosis. Patients <35 and 35-39 years old were more likely to present with higher risk features, HER2 positive or triple-negative biomarkers, and more advanced TNM stage at diagnosis. They were more likely to undergo treatment with mastectomy, axillary lymph node dissection, radiotherapy and chemotherapy. Conversely, patients ≥80 years old were generally more likely to have hormone-sensitive HER2-negative disease, and lower TNM stage at diagnosis. They were less likely to undergo surgery or be treated with radiotherapy and chemotherapy. Both younger and elderly age at breast cancer diagnosis were independent risk factors for poorer prognosis after controlling for subtype, LVI, stage, and treatment factors. This work will help clinicians to more accurately estimate patient outcomes, patterns of relapse, and provide evidence-based treatment recommendations.

摘要

先前关于乳腺癌诊断时年龄对患者结局和生存影响的数据存在争议。本研究利用不列颠哥伦比亚癌症局的乳腺癌结局单位数据库,对 2005 年至 2014 年间诊断为浸润性乳腺癌的 24469 例患者进行了回顾性基于人群的研究。中位随访时间为 11.5 年。我们分析了诊断时的临床和病理特征以及治疗特异性变量,并在以下年龄组之间进行了比较:<35 岁、35-39 岁、40-49 岁、50-59 岁、60-69 岁、70-79 岁和 80 岁及以上。我们按年龄和亚型评估了年龄对乳腺癌特异性生存(BCSS)和总生存(OS)的影响。在诊断时的年龄两端,均存在明显的临床病理和治疗模式差异。<35 岁和 35-39 岁的患者更有可能表现出更高的风险特征、HER2 阳性或三阴性生物标志物以及更晚期的 TNM 分期。他们更有可能接受乳房切除术、腋窝淋巴结清扫术、放疗和化疗。相反,≥80 岁的患者通常更有可能患有激素敏感型 HER2 阴性疾病,且诊断时的 TNM 分期较低。他们不太可能接受手术或接受放疗和化疗。在控制亚型、LVI、分期和治疗因素后,乳腺癌诊断时年龄较小和较大都是预后较差的独立危险因素。这项工作将帮助临床医生更准确地估计患者的结局、复发模式,并提供基于证据的治疗建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验